BRIEF-Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics

Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc.

SNSE

0.00

June 15 (Reuters) - Sensei Biotherapeutics Inc SNSE.O:

  • SENSEI BIOTHERAPEUTICS ANNOUNCES NAME CHANGE TO FAETH THERAPEUTICS, FOCUSED ON ADVANCING PIKTOR, AN ORAL THERAPY TARGETING ONE OF THE MOST FREQUENTLY ALTERED PATHWAYS IN CANCER

  • SENSEI BIOTHERAPEUTICS - COMMON STOCK TO BEGIN TRADING AS FTH ON NASDAQ ON JUNE 16, 2026

  • SENSEI BIOTHERAPEUTICS - APPOINTS ANAND PARIKH AS CHAIRMAN, PRESIDENT AND CEO EFFECTIVE JUNE 12, 2026

  • SENSEI BIOTHERAPEUTICS - APPOINTS BRIAN STEPHENSON AS CHIEF FINANCIAL OFFICER

  • SENSEI BIOTHERAPEUTICS - PIKTOR PHASE 2 TOPLINE DATA IN ADVANCED ENDOMETRIAL CANCER EXPECTED SECOND HALF 2026

  • SENSEI BIOTHERAPEUTICS - PIKTOR PHASE 1B/2 INTERIM DATA IN HR+/HER2- ADVANCED BREAST CANCER EXPECTED IN 2027

Source text: ID:nBw48Dc9ra

Further company coverage: SNSE.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.